问象观察站/今日概览

Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases

Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Tue Oct 13 2026 20:30:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Tue Oct 13 2026 21:08:11 GMT+0000 (Coordinated Universal Time)

Original sources

Saved source excerpt

Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third

This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.

How to assess model and industry evidence →

The interface and original reader guides use the selected language. Source titles, excerpts, event summaries, and evidence quotations retain their original language.

访问统计与隐私说明

本站用第一方统计了解哪些页面、原始出处与连接功能受到关注。统计记录仅含允许的页面路径、动作标识和来源域名,不含搜索词、表单内容、完整链接或原始 IP。

匿名会话标识仅保存在当前标签页,30 分钟没有活动后更新,不代表独立人数。浏览器的 Do Not Track(DNT)或 Global Privacy Control(GPC)信号会停止网页事件采集;管理页面和管理操作不采集。

MCP 使用量由服务端实际执行的工具记录,网页复制按钮点击不会算作工具调用,也不证明复制成功。测试流量与按浏览器标识识别的自动化访问从网页统计排除,识别可能存在误差;统计事件保留 90 天。